Literature DB >> 10833486

Liver fibrosis in overweight patients.

V Ratziu1, P Giral, F Charlotte, E Bruckert, V Thibault, I Theodorou, L Khalil, G Turpin, P Opolon, T Poynard.   

Abstract

BACKGROUND & AIMS: A common clinical issue is whether overweight patients with abnormal liver function test results should undergo liver biopsy. Although serious liver injury can occur, its prevalence and risk factors are not well known.
METHODS: Ninety-three consecutive patients with abnormal liver function tests (but without overt liver disease), body mass index (BMI) > 25 kg/m(2), and no alcoholic, viral, autoimmune, drug-induced, or genetic liver disease were retrospectively studied. Clinical, biological, and histological variables were tested for association with septal fibrosis or cirrhosis.
RESULTS: Septal fibrosis was present in 28 patients (30%) including cirrhosis in 10 (11%). Age >/= 50 years (odds ratio [OR], 14.1), BMI >/= 28 kg/m(2) (OR, 5.7), triglycerides >/= 1.7 mmol/L (OR, 5), and alanine aminotransferase (ALT) >/= 2N (OR, 4.6) were independently associated with septal fibrosis. Among histological features, septal fibrosis was strongly associated with necroinflammatory activity (OR, 44). A score combining age, BMI, triglycerides, and ALT had 100% negative predictive value for septal fibrosis when scoring 0 or 1 (100% sensitivity for a specificity of 47%).
CONCLUSIONS: Septal fibrosis occurs frequently in overweight patients with abnormal liver function tests. A clinicobiological score combining BMI, age, ALT, and triglycerides could improve selection of patients for liver biopsy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833486     DOI: 10.1016/s0016-5085(00)70364-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  208 in total

Review 1.  Mallory-Denk Bodies in chronic hepatitis.

Authors:  Metin Basaranoglu; Nesrin Turhan; Abdullah Sonsuz; Gökcen Basaranoglu
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

2.  Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis.

Authors:  Akihiko Osaki; Tomoyuki Kubota; Takeshi Suda; Masato Igarashi; Keisuke Nagasaki; Atsunori Tsuchiya; Masahiko Yano; Yasushi Tamura; Masaaki Takamura; Hirokazu Kawai; Satoshi Yamagiwa; Toru Kikuchi; Minoru Nomoto; Yutaka Aoyagi
Journal:  World J Gastroenterol       Date:  2010-06-21       Impact factor: 5.742

3.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

Review 4.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

5.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

Authors:  Savino Bruno; Patrick Maisonneuve; Paola Castellana; Nicole Rotmensz; Sonia Rossi; Marco Maggioni; Marcello Persico; Alberto Colombo; Franco Monasterolo; Donata Casadei-Giunchi; Franco Desiderio; Tommaso Stroffolini; Virgilio Sacchini; Andrea Decensi; Umberto Veronesi
Journal:  BMJ       Date:  2005-03-03

Review 7.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 8.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

9.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

10.  Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients.

Authors:  Matthew Kroh; Rockson Liu; Bipan Chand
Journal:  Surg Endosc       Date:  2007-05-04       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.